Humacyte Accounts Payable from 2010 to 2024
HUMAW Stock | USD 1.69 0.11 6.96% |
Accounts Payable | First Reported 2010-12-31 | Previous Quarter 6.5 M | Current Value 3.5 M | Quarterly Volatility 1.1 M |
Check Humacyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Humacyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 M, Interest Expense of 1.1 M or Selling General Administrative of 21.1 M, as well as many indicators such as Price To Sales Ratio of 96.95, Dividend Yield of 0.0 or PTB Ratio of 22.77. Humacyte financial statements analysis is a perfect complement when working with Humacyte Valuation or Volatility modules.
Humacyte | Accounts Payable |
Latest Humacyte's Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Humacyte over the last few years. An accounting item on the balance sheet that represents Humacyte obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Humacyte are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Humacyte's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Humacyte's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable | 10 Years Trend |
|
Accounts Payable |
Timeline |
Humacyte Accounts Payable Regression Statistics
Arithmetic Mean | 3,242,167 | |
Geometric Mean | 3,104,521 | |
Coefficient Of Variation | 32.53 | |
Mean Deviation | 501,800 | |
Median | 3,272,000 | |
Standard Deviation | 1,054,695 | |
Sample Variance | 1.1T | |
Range | 4.9M | |
R-Value | 0.07 | |
Mean Square Error | 1.2T | |
R-Squared | 0 | |
Significance | 0.81 | |
Slope | 16,177 | |
Total Sum of Squares | 15.6T |
Humacyte Accounts Payable History
About Humacyte Financial Statements
Humacyte investors use historical fundamental indicators, such as Humacyte's Accounts Payable, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Humacyte. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Accounts Payable | 6.5 M | 3.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.